Biomerieux
bioMérieux, a global leader in in vitro diagnostics, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 1963, the company has consistently innovated in the fields of microbiology and molecular biology, achieving significant milestones such as the development of the first automated microbiology system. Specialising in diagnostic solutions for infectious diseases, bioMérieux offers a range of unique products, including rapid tests and automated systems that enhance laboratory efficiency and accuracy. Their commitment to quality and innovation has solidified their position as a trusted partner in healthcare, with notable achievements in improving patient outcomes through timely diagnostics. With a strong focus on research and development, bioMérieux continues to lead the way in advancing diagnostic technologies worldwide.
DitchCarbon Score
How does Biomerieux's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biomerieux's score of 64 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biomerieux's reported carbon emissions
In 2023, bioMérieux reported total greenhouse gas emissions of approximately 1,124,000,000 kg CO2e, with emissions distributed across various scopes: 23,000,000 kg CO2e (Scope 1), 39,000,000 kg CO2e (Scope 2), and 1,124,000,000 kg CO2e (Scope 3). The company has set ambitious climate commitments, aiming for a 63% reduction in absolute Scope 1 and 2 emissions by 2034, using 2019 as the baseline year. This target aligns with the Science Based Targets initiative (SBTi) and is designed to support global efforts to limit temperature rise to 1.5°C. Additionally, bioMérieux has committed that by 2026, 67% of its suppliers, based on emissions from purchased goods and services, fuel and energy-related activities, and other categories, will also have science-based targets. The company previously aimed for a 50% reduction in Scope 1 and 2 emissions by 2030 compared to 2019 levels, demonstrating a strong commitment to sustainability and climate action within the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 26,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 39,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 891,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biomerieux is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
